Minh-hang Chau, M.D. Urology Medicare: Medicare Enrolled Practice Location: 11370 Anderson St, Ste 1100, Loma Linda, CA 92354 Phone: 909-558-2830 |
Dr. Keith Francis Rourke, MD, FRCSC Urology Medicare: Not Enrolled in Medicare Practice Location: 11234 Anderson St Rm A560, Loma Linda, CA 92354 Phone: 877-558-6248 Fax: 909-558-4806 |
Noel T Hui, M.D. Urology Medicare: Medicare Enrolled Practice Location: 11370 Anderson St, Suite 1100, Loma Linda, CA 92354 Phone: 909-558-4830 Fax: 909-558-3905 |
News Archive
AZ-TMJ is once again leading the way in innovative and effective treatments for severe cases of Temporomandibular Joint Disorders or TMD. AZ-TMJ has developed a variety of highly effective treatments to greatly reduce the frequency and severity of migraine headaches for a large percentage of sufferers. Approximately 16% to 17% of the population suffers from migraine headaches, which often have a debilitating effect on suffers' daily lives.
Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.
Some people are oblivious to the odor in the locker room after a game, while others wrinkle their noses at the slightest whiff of sweat.
A new study has shown that laughter may be one of the simplest exercises that has similar effects on the body as pumping iron in the gym. Researchers have named "Laughercise" as significant elevators of mood, stress busters, immunity boosters and blood pressure and cholesterol reducers. It can also stimulate appetite for the malnourished.
Keryx Biopharmaceuticals, Inc., announced today that its Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd., has announced positive top-line results from a Phase 3 study of ferric citrate in Japan for the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis.
› Verified 5 days ago